Novartis halts CAR-T trials after three patient deaths from an immune overreaction; Bristol Myers pauses zola-cel enrollment.
Three patients died in Novartis trials of its CD19-directed CAR-T treatment following a dangerous immune system response, and a similar therapy from Bristol Myers Squibb …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Novartis, Bristol Myers halt autoimmune CAR-T trials after deaths
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Will Patient Deaths Derail the CAR-T Train in Autoimmune Disease?
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Novartis halts clinical trials following patient deaths
Novartis pauses trials of experimental cell therapy after three deaths - Health - The Jakarta Post
Novartis suspende testes de medicamento para doenças autoimunes após morte de três pacientes
Novartis suspende testes clínicos de medicamento para doenças autoimunes após morte de três pacientes
Pharmakonzern Novartis stoppt nach Todesfällen mehrere Studien
Novartis pausa ensaios de terapia voltada a distúrbios autoimunes e neurológicos após três mortes
Novartis paused 8 trials of its rap-cel therapy after patients died from a severe immune reaction; Bristol Myers followed as a…
The deaths of three study participants led Novartis to halt development of rap-cel in multiple indications, while “transient”…
Three patient deaths in Novartis' autoimmune CAR-T trials raise questions about risks of the therapy in non-fatal diseases.
Novartis, BMS reportedly halt trials; first serious blow to burgeoning field
Welcome back to Endpoints Weekly. Endpoints News broke the news this week on the deaths of three patients who received Novartis’…
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could…
